Table 1: PCSK9 inhibitors showed a tendency to reduce the cardiovascular mortality rate.
Trial Patients, n Disease Intervention Follow-up period Cardiovascular events Hazard ratio 95% CI P
OSLER16 4465 statin-intolerant, heterozygous familial hypercholesterolemia or inadequate control of LDL cholesterol levels with statins evolocumab 420 mg once a month or 140 mg every 2 weeks 11.1 months death, myocardial infarction, unstable angina, coronary revascularization, stroke, transient ischemic attack, or heart failure 0.47 0.28–0.78 0.003
ODYSSEY LONG TERM17 2341 heterozygous familial hypercholesterolemia, coronary heart disease, or coronary heart disease equivalent with LDL cholesterol levels ≥ 70 mg/dL alirocumab 150 mg every 2 weeks 80 weeks death from coronary heart disease, non-fatal myocardial infarction, fatal or non-fatal ischemic stroke, or unstable angina requiring hospitalization 0.52 0.31–0.90 0.02
Patients, n Disease Intervention Cardiovascular events Odds ratio 95% CI P
Meta-analysis18 10159 adult hypercholesterolemia evolocumab or alirocumab All-cause mortality
Cardiovascular mortality
Myocardial infarction		 0.45
0.5
0.49		 0.23–0.86
0.23–1.10
0.26–0.93		 0.015
0.084
0.03